Dedicated to Developing Novel Medicines for CNS Diseases

About Us

Committed to Advancing a New Generation of Oral Antidepressants

AV-101, an NMDA receptor glycine-binding site antagonist, is a new generation oral antidepressant drug candidate in Phase 2 development, inspired by breakthrough clinical studies involving ketamine. The mechanism of action of AV-101, and that of ketamine, is fundamentally differentiated from all FDA-approved antidepressants.

VistaGen Therapeutics, Inc. Pipeline
What Makes AV-101 Different?

Going Above and Beyond Current Treatment Options

Focused on providing novel solutions for millions of drug-treated depression patients with inadequate response to current depression therapies.

Learn More About Ketamine and AV-101

Backed by an Experienced Leadership Team

Our highly experienced management team, board of directors and clinical and regulatory advisory board have a proven track record of developing innovative drugs to treat CNS diseases.

Meet Our Team

Stock Information

View Detailed Stock Info
NASDAQ: VTGN Symbol
Price
Change
Volume
Day Range
52 Week Range

Corporate Presentation

For Investors

Email Updates

Be the first to receive news, events & updates Sign Up